NKTR Initiates Phase III for Rezpeg in Atopic Dermatitis, but Timing Misses Key Milestone

What happened

Nektar Therapeutics announced the start of two Phase III ZENITH AD studies for rezpegaldesleukin in moderate-to-severe atopic dermatitis, with a third study slated to begin in September. The news drove shares higher, yet the initiation comes after the June 2026 deadline set in our February analysis as a key catalyst for increasing conviction. While the company has moved from Phase IIb to pivotal trials, the delay relative to the guided Q2 2026 start signals potential operational friction—consistent with our earlier concerns around CMC readiness and financing execution. The $300M equity offering announced in February has not been fully de-risked, as the terms and closing remain unconfirmed, and the Phase III start does not by itself resolve the funding gap or the responder-enriched durability caveats in the Phase IIb data.

Implication

Long-term investors should remain cautious. The Phase III start is a necessary step, but the program still faces significant hurdles: manufacturing comparability, patient population finalization, and the need for large-scale financing. The delay likely means higher cumulative costs and potential further dilution. Wait for confirmation of financing terms (preferably near-market) and see if the Phase III trial protocols match the FDA-aligned endpoints (EASI-75 + IGA). If the offering was priced at a discount or if enrollment slips further, the risk/reward shifts negative.

Thesis delta

Our WAIT thesis from February was predicated on two conditions: Phase III starts by Q2 2026 and the $300M offering closes near $65. The Phase III start has occurred, but in July—after Q2—which weakens the bullish trigger. The offering's status remains opaque, and no partnership deal has emerged to reduce dilution. This combination lowers conviction and suggests the stock may have already priced in this catalyst. The thesis now shifts from 'wait for Phase III start' to 'wait for proof of financing terms and enrollment execution.' The attractive entry of $50 is no longer relevant at current prices (likely above $65), and the trim-above-$95 level should be revisited only if both conditions are met cleanly.